|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, loss of Fgf13 reduced in vitro cell migration, suggesting that Fgf13 may be critical for tumor cells to escape the primary tumor and to colonize the distal sites.
|
31341204 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
At pathophysiologically relevant concentrations found in tumor interstitial fluid, sHA is pro-proliferative, acts synergistically with VEGF-C and FGF-2, and stimulates the outgrowth of lymphatic capillaries in ex vivo lymphangiogenesis assays.
|
29282520 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dual roles of endothelial FGF-2-FGFR1-PDGF-BB and perivascular FGF-2-FGFR2-PDGFRβ signaling pathways in tumor vascular remodeling.
|
29423271 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, stimulation of non-metastasis-promoting normal fibroblasts with TGF-B, FGF-2, HGF, and PDGF-BB led to acquisition of their metastatic capacity.<b>Conclusions:</b> Cancer metastasis occurs at the very early stage of tumor formation consisting of only a few hundred cells.
|
28420724 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings may indicate a novel role of NCAM- and FGF-2-mediated FGFR1 signaling in the tumor microenvironment of ESCCs.
|
27317650 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In lung cancer cells, depletion of eIF4H enhances sensitization to chemotherapy, decreases cell migration and inhibits tumor growth in vivo, in association with reduced translation of mRNA encoding cell-proliferation (c-Myc, cyclin D1) angiogenic (FGF-2) and anti-apoptotic factors (CIAP-1, BCL-xL).
|
26498689 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth.
|
24874473 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Such downregulation of miR-15 and miR-16 in cancer-associated fibroblasts (CAFs) promoted tumor growth and progression through the reduced post-transcriptional repression of Fgf-2 and its receptor Fgfr1, which act on both stromal and tumor cells to enhance cancer cell survival, proliferation and migration.
|
21532615 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, peritumoral mast cells provide FGF-2 to the tumor micro environment, which may contribute to their stimulating effect on angiogenesis.
|
20616342 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To obtain some clues about this cross-talk and also to better understand our previous immunoprofile study of myoepithelial cells in salivary gland carcinoma ex-pleomorphic adenoma (CXPA), we investigated FGF-2 expression in CXPA in situ structures as well as in cells cultured under conditions attempting to simulate the cellular interactions of this tumor stage.
|
20514456 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cytoplasmic PTTG expression correlated with expression of progesterone receptor (P = 0.009) and FGF-2 (P = 0.007) but not with other parameters such as the expression of estrogen receptor, tumor grade, and surgical stage.
|
18217976 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
FGF-2 was downregulated in tumor tissue.
|
19245594 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A truncated form of 24kDa FGF-2 consisting of 86 NH(2)-terminal amino acids (ATE+31) inhibits cell migration in vitro and tumor development and angiogenesis in vivo.
|
19303400 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry of the excised tumor revealed strong immunoreactivity for VEGF and FGF-2, two potent angiogenic factors, and CD31 (an endothelial marker) indicating high vascularization of the adenoma.
|
19172414 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, in vivo, the FGFR inhibitor decreased C4-HI tumor growth, whereas FGF-2 was able to stimulate C4-HD tumor growth as MPA.
|
18767044 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This indicates that HMW FGF-2 inhibits tumor growth in glioma cells by acting on cell-cycle progression and protein translation.
|
18930044 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Neutralizing FGFR1-specific antibody abrogates the physiologic and chemoprotective effects of FGF-2/FGFR1beta signaling and inhibits tumor growth in mice xenotransplanted with human AML.
|
16598308 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, our current study indicates that the PDGFRalpha-p70S6K pathway is an essential regulator for FGF-2-mediated therapeutic neovascularization, as well as for the host-derived vasculature but not tumors during tumor angiogenesis, via controlling continuity of expression of multiple angiogenic growth factors.
|
15059936 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased FGF-2 mRNA expression was independently associated with the findings of lymph node invasion (R(2) = 0.71; P < 0.001) and distant metastasis (R(2) = 0.55; P = 0.009) at tumor presentation, after taking into account known prognostic factors such as age and gender of the patient and size and type of the tumor.
|
12727994 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
4E facilitates the synthesis of two powerful tumor angiogenic factors (VEGF and FGF-2) by selectively enhancing their translation.
|
10443829 |
1999 |